Do analysts prefer EVAX or XBIO?

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 259.48%. Given Evaxion A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Evaxion A/S is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend XBIO or ATNM?

Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 527.04%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend XBIO or LGVN?

Longeveron has a consensus target price of $5.50, indicating a potential upside of 618.02%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate XBIO or BRNS?

Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 567.78%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer MDXH or XBIO?

MDxHealth presently has a consensus price target of $3.50, indicating a potential upside of 659.22%. Given MDxHealth's stronger consensus rating and higher probable upside, equities analysts plainly believe MDxHealth is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Xenetic Biosciences (XBIO) Competitors

$3.17 +0.32 (+11.23%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$3.15 -0.02 (-0.66%)

As of 08/7/2026 07:00 PM Eastern

Compare

XBIO vs. EVAX, ATNM, LGVN, BRNS, and MDXH

Should you buy Xenetic Biosciences stock or one of its competitors? MarketBeat compares Xenetic Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xenetic Biosciences include Evaxion A/S (EVAX), Actinium Pharmaceuticals (ATNM), Longeveron (LGVN), Barinthus Biotherapeutics (BRNS), and MDxHealth (MDXH). These companies are all part of the "biotechnology" industry.

How does Xenetic Biosciences compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 259.48%. Given Evaxion A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Evaxion A/S is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evaxion A/S has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

In the previous week, Evaxion A/S and Evaxion A/S both had 1 articles in the media. Evaxion A/S's average media sentiment score of 0.00 beat Xenetic Biosciences' score of -0.47 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Neutral
Xenetic Biosciences	Neutral

Evaxion A/S has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market.

Xenetic Biosciences has lower revenue, but higher earnings than Evaxion A/S. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.39	-$7.71M	-$1.47	N/A
Xenetic Biosciences	$2.98M	2.44	-$2.68M	-$1.20	N/A

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Evaxion A/S beats Xenetic Biosciences on 9 of the 15 factors compared between the two stocks.

How does Xenetic Biosciences compare to Actinium Pharmaceuticals?

Xenetic Biosciences (NASDAQ:XBIO) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Xenetic Biosciences has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Xenetic Biosciences has higher revenue and earnings than Actinium Pharmaceuticals. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.44	-$2.68M	-$1.20	N/A
Actinium Pharmaceuticals	$90K	277.98	-$48.82M	-$0.75	N/A

In the previous week, Xenetic Biosciences had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 1 mentions for Xenetic Biosciences and 0 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.00 beat Xenetic Biosciences' score of -0.47 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Xenetic Biosciences	Neutral
Actinium Pharmaceuticals	Neutral

Actinium Pharmaceuticals has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 527.04%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Actinium Pharmaceuticals beats Xenetic Biosciences on 9 of the 16 factors compared between the two stocks.

How does Xenetic Biosciences compare to Longeveron?

Xenetic Biosciences (NASDAQ:XBIO) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Longeveron has a consensus target price of $5.50, indicating a potential upside of 618.02%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Xenetic Biosciences and Xenetic Biosciences both had 1 articles in the media. Longeveron's average media sentiment score of 0.00 beat Xenetic Biosciences' score of -0.47 indicating that Longeveron is being referred to more favorably in the news media.

Company	Overall Sentiment
Xenetic Biosciences	Neutral
Longeveron	Neutral

Xenetic Biosciences has a net margin of -70.03% compared to Longeveron's net margin of -1,844.49%. Xenetic Biosciences' return on equity of -39.28% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Longeveron	-1,844.49%	-202.41%	-140.67%

Xenetic Biosciences has higher revenue and earnings than Longeveron. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.44	-$2.68M	-$1.20	N/A
Longeveron	$1.20M	19.88	-$22.70M	-$1.13	N/A

Xenetic Biosciences has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market.

Summary

Xenetic Biosciences beats Longeveron on 8 of the 15 factors compared between the two stocks.

How does Xenetic Biosciences compare to Barinthus Biotherapeutics?

Xenetic Biosciences (NASDAQ:XBIO) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Xenetic Biosciences has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

In the previous week, Xenetic Biosciences and Xenetic Biosciences both had 1 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 1.50 beat Xenetic Biosciences' score of -0.47 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Xenetic Biosciences	Neutral
Barinthus Biotherapeutics	Very Positive

Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 567.78%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Xenetic Biosciences has higher earnings, but lower revenue than Barinthus Biotherapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.44	-$2.68M	-$1.20	N/A
Barinthus Biotherapeutics	$14.97M	1.63	-$66.43M	-$1.29	N/A

Barinthus Biotherapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Barinthus Biotherapeutics	N/A	-55.61%	-41.83%

Summary

Barinthus Biotherapeutics beats Xenetic Biosciences on 9 of the 15 factors compared between the two stocks.

How does Xenetic Biosciences compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

15.1% of Xenetic Biosciences shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MDxHealth has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market.

Xenetic Biosciences has lower revenue, but higher earnings than MDxHealth. Xenetic Biosciences is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.21	-$33.52M	-$0.65	N/A
Xenetic Biosciences	$2.98M	2.44	-$2.68M	-$1.20	N/A

In the previous week, MDxHealth and MDxHealth both had 1 articles in the media. MDxHealth's average media sentiment score of 0.00 beat Xenetic Biosciences' score of -0.47 indicating that MDxHealth is being referred to more favorably in the media.

Company	Overall Sentiment
MDxHealth	Neutral
Xenetic Biosciences	Neutral

MDxHealth has a net margin of -29.90% compared to Xenetic Biosciences' net margin of -70.03%. MDxHealth's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-29.90%	N/A	-22.51%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

MDxHealth presently has a consensus price target of $3.50, indicating a potential upside of 659.22%. Given MDxHealth's stronger consensus rating and higher probable upside, equities analysts plainly believe MDxHealth is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MDxHealth beats Xenetic Biosciences on 10 of the 15 factors compared between the two stocks.

Get Xenetic Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIO vs. The Competition

Export

Metric	Xenetic Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.53M	$3.62B	$6.93B	$12.86B
Dividend Yield	N/A	3.77%	2.59%	9.91%
P/E Ratio	-2.64	8.94	270.28	25.05
Price / Sales	2.44	1,271.42	597.39	99.22
Price / Cash	N/A	98.58	71.46	49.72
Price / Book	0.98	18.10	13.25	6.21
Net Income	-$2.68M	-$13.22M	$3.45B	$342.45M
7 Day Performance	24.80%	6.27%	4.65%	4.41%
1 Month Performance	16.97%	-2.67%	-0.79%	-0.28%
1 Year Performance	14.44%	61.22%	77.75%	22.60%

Xenetic Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIO Xenetic Biosciences	0.9105 of 5 stars	$3.17 +11.2%	N/A	+6.7%	$6.53M	$2.98M	N/A	4	News Coverage Earnings Report High Trading Volume
EVAX Evaxion A/S	2.6817 of 5 stars	$2.98 +1.0%	$11.00 +269.1%	+4.4%	$24.60M	$7.53M	N/A	60	News Coverage Upcoming Earnings Gap Up
ATNM Actinium Pharmaceuticals	1.7275 of 5 stars	$0.75 -7.6%	$5.00 +567.8%	-48.9%	$23.49M	$90K	N/A	30	News Coverage High Trading Volume
LGVN Longeveron	1.7215 of 5 stars	$0.73 -2.0%	$5.50 +656.4%	-39.7%	$23.11M	$1.20M	N/A	20	Upcoming Earnings
BRNS Barinthus Biotherapeutics	3.1565 of 5 stars	$0.59 +3.8%	$4.00 +582.6%	-58.7%	$23.07M	$14.97M	N/A	107	News Coverage Positive News Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIO) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenetic Biosciences (XBIO) Competitors

XBIO vs. EVAX, ATNM, LGVN, BRNS, and MDXH

How does Xenetic Biosciences compare to Evaxion A/S?

Summary

How does Xenetic Biosciences compare to Actinium Pharmaceuticals?

Summary

How does Xenetic Biosciences compare to Longeveron?

Summary

How does Xenetic Biosciences compare to Barinthus Biotherapeutics?

Summary

How does Xenetic Biosciences compare to MDxHealth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenetic Biosciences (XBIO) Competitors

XBIO vs. EVAX, ATNM, LGVN, BRNS, and MDXH

How does Xenetic Biosciences compare to Evaxion A/S?

Do analysts prefer EVAX or XBIO?

Is EVAX or XBIO more profitable?

Does the media favor EVAX or XBIO?

Which has more risk & volatility, EVAX or XBIO?

Which has preferable valuation and earnings, EVAX or XBIO?

Do insiders & institutionals believe in EVAX or XBIO?

Summary

How does Xenetic Biosciences compare to Actinium Pharmaceuticals?

Which has more volatility & risk, XBIO or ATNM?

Which has higher valuation and earnings, XBIO or ATNM?

Does the media refer more to XBIO or ATNM?

Is XBIO or ATNM more profitable?

Do institutionals & insiders believe in XBIO or ATNM?

Do analysts recommend XBIO or ATNM?

Summary

How does Xenetic Biosciences compare to Longeveron?

Do analysts recommend XBIO or LGVN?

Do institutionals and insiders believe in XBIO or LGVN?

Does the media refer more to XBIO or LGVN?

Is XBIO or LGVN more profitable?

Which has preferable earnings & valuation, XBIO or LGVN?

Which has more risk and volatility, XBIO or LGVN?

Summary

How does Xenetic Biosciences compare to Barinthus Biotherapeutics?

Do insiders & institutionals believe in XBIO or BRNS?

Which has more volatility and risk, XBIO or BRNS?

Does the media refer more to XBIO or BRNS?

Do analysts rate XBIO or BRNS?

Which has better earnings & valuation, XBIO or BRNS?

Is XBIO or BRNS more profitable?

Summary

How does Xenetic Biosciences compare to MDxHealth?

Do institutionals & insiders believe in MDXH or XBIO?

Which has more risk & volatility, MDXH or XBIO?

Which has stronger valuation & earnings, MDXH or XBIO?

Does the media prefer MDXH or XBIO?

Is MDXH or XBIO more profitable?

Do analysts prefer MDXH or XBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools